ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Lung Cancer - Multimodality Therapy

January 10, 2020
Declines in US annual lung cancer mortality rates of 5% for men and 4% for women led improvements in overall cancer mortality rates in the latest update from the American Cancer Society. This is likely linked to efforts at decreasing tobacco use, improved screening, and newer systemic therapies.
November 7, 2019
This brief overview of recently presented improvements in lung cancer therapy highlights the substantial benefits of newer chemotherapy and immunotherapy regimens that are transforming the outlooks of many patients with advanced lung cancer.
August 8, 2019
A detailed and robust meta-analysis asserting lack of strong evidence supporting either modality.
June 13, 2019
To evaluate the benefit of multimodality treatment for patients with limited disease small-cell lung cancer, Weckler and colleagues retrospectively reviewed outcomes for 47 patients treated at their institution between 1999 and 2016.
April 17, 2019
Dr Burt gives a brief overview of the considerable advances for patients with thoracic malignancies (non–small cell lung cancer in particular).
March 4, 2019
The complete pathologic response rate in this study is revealed to be low, lower than expected after stereotactic ablative radiotherapy (SABR) for early stage non-small cell lung cancer: only 60%. The authors suggest a combined approach (SABR plus surgery), adopted in this experimental phase 2 trial, as a possible management scheme.
October 23, 2018
Forty-nine patients with limited metastatic non-small cell lung cancer (three or fewer metastatic sites) who did not progress on initial systemic therapy were randomized to surgery or RT vs standard maintenance therapy.  Overall survival for the intervention group was 41.2 mos vs 17.0 mos in those getting maintenance therapy (p=0.017). 
September 25, 2018
This comprises the eagerly anticipated summary of the second primary endpoint of the PACIFIC trial of Durvalumab vs placebo in patients who completed CT/RT without progression for unresectable stage III NSCLC. Durvalumab significantly improved overall survival, progression free survival, and time to distant metastasis or death.
August 20, 2018
This provocative editorial outlines concepts that thoracic surgeons should understand in the era of immunotherapy for potentially resectable N2 disease.
July 5, 2018
Gilbert Massard of the Centre Hospitalier in Strasbourg, France, discusses difficult decisions in lung cancer treatment.

Pages